UMCG and RaySearch Initiate Collaboration Within Adaptive Radiation Therapy
News Oct 14, 2013
RaySearch Laboratories AB has received an order for its RayStation® treatment planning system from University Medical Center Groningen (UMCG) in Groningen, the Netherlands.
In conjunction with this, RaySearch and UMCG will also initiate a new research collaboration project.
UMCG is one of the largest hospitals in the Netherlands and the largest employer in the Northern Netherlands. More than 10,000 employees provide patient care, are involved in medical education and perform cutting-edge scientific research, focused on ‘healthy and active ageing’.
Research and education at the UMCG are funded through the University of Groningen, and the Faculty of Medical Sciences functions as an integral part of the University.
More than 3,400 students of the University of Groningen study Medicine, Dentistry or Human Movement Sciences, while more than 340 physicians are doing their specialty training at the state of the art facilities of the UMCG.
RaySearch and the department of Radiation Oncology of UMCG have a longstanding research cooperation that will now be focused on adaptive radiation therapy using RayStation®.
Adaptive therapy is an advanced form of radiation therapy where the delivered dose is adjusted continuously during the course of treatment to account for changes occurring in the patient’s anatomy. This has a significant potential to increase the tumor control probability and at the same time reduce the risk for side effects by sparing healthy tissue.
UMCG and RaySearch will now collaborate to introduce adaptive radiation therapy in clinical practice and further refine and evaluate the methods involved.
“RaySearch is a pioneer in the development of advanced software tools for radiation therapy and our longstanding cooperation is highly important for our department. RayStation® is the leading tool on the market for adaptive radiation therapy and we are very excited to start implementing this concept with a significant potential to improve cancer care”, says Prof. Johannes A. Langendijk, chair of the Department of Radiation Oncology at University Medical Center Groningen.
“UMCG is a well-renowned clinic and have proven over the years that they maintain an excellent standard in cancer research. I am therefore convinced that this collaboration will be very fruitful and will make meaningful contributions to the area of adaptive radiation therapy which is the most important new concept in radiation therapy”, says Johan Löf, CEO of RaySearch.
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers say they have identified that target - an enzyme called PPT1 - opening up a new pathway for potential cancer treatments.READ MORE